Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

0.9871 -0.0229 (-2.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Volume	285,404
Open	1.000
Bid (Size)	0.9798 (700)
Ask (Size)	1.000 (1,400)
Prev. Close	1.010
Today's Range	0.9700 - 1.006
52wk Range	0.9657 - 4.190
Shares Outstanding	5,726,750
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

January 26, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

January 20, 2026

Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable...

Via Newsfile

Performance

YTD	-9.4%	-9.4%
1 Month	-15.6%	-15.6%
3 Month	-46.9%	-46.9%
6 Month	-58.4%	-58.4%
1 Year	-51.6%	-51.6%

More News

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

January 15, 2026

Via Newsfile

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

December 23, 2025

Via Newsfile

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

November 25, 2025

Via Newsfile

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

November 17, 2025

Via Newsfile

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025

Via Newsfile

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

November 07, 2025

Via Newsfile

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

November 07, 2025

Via Newsfile

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

These stocks are the most active in today's session ↗

November 03, 2025

Via Chartmill

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

November 03, 2025

Via Newsfile

Why Is Phio Pharmaceuticals Stock Soaring Today? ↗

November 03, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

Via Chartmill

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

November 03, 2025

Via Newsfile

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

October 31, 2025

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

October 21, 2025

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

September 23, 2025

Via Newsfile

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

September 18, 2025

Via Newsfile

Frequently Asked Questions

Is Phio Pharmaceuticals Corp. - Common Stock publicly traded?

Yes, Phio Pharmaceuticals Corp. - Common Stock is publicly traded.

What exchange does Phio Pharmaceuticals Corp. - Common Stock trade on?

Phio Pharmaceuticals Corp. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Phio Pharmaceuticals Corp. - Common Stock?

The ticker symbol for Phio Pharmaceuticals Corp. - Common Stock is PHIO on the Nasdaq Stock Market

What is the current price of Phio Pharmaceuticals Corp. - Common Stock?

The current price of Phio Pharmaceuticals Corp. - Common Stock is 0.9871

When was Phio Pharmaceuticals Corp. - Common Stock last traded?

The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 02/02/26 04:00 PM ET

What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?

The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 5.65M

How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?

Phio Pharmaceuticals Corp. - Common Stock has 6M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.